Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Gains from Investment Securities (2020 - 2022)

PROCEPT BioRobotics has reported Gains from Investment Securities over the past 3 years, most recently at $186000.0 for Q4 2022.

  • Quarterly Gains from Investment Securities rose 390.62% to $186000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $122000.0 through Dec 2023, up 15.09% year-over-year, with the annual reading at $22.9 million for FY2022, 35809.38% up from the prior year.
  • Gains from Investment Securities was $186000.0 for Q4 2022 at PROCEPT BioRobotics, up from -$64000.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $293000.0 in Q4 2020 and troughed at -$142000.0 in Q3 2020.
  • The 3-year median for Gains from Investment Securities is -$20000.0 (2021), against an average of $38833.3.
  • Year-over-year, Gains from Investment Securities crashed 121.84% in 2021 and then skyrocketed 390.62% in 2022.
  • A 3-year view of Gains from Investment Securities shows it stood at $293000.0 in 2020, then tumbled by 121.84% to -$64000.0 in 2021, then skyrocketed by 390.62% to $186000.0 in 2022.
  • Per Business Quant, the three most recent readings for PRCT's Gains from Investment Securities are $186000.0 (Q4 2022), -$64000.0 (Q4 2021), and -$16000.0 (Q3 2021).